Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTION-2: Intravenous Tenecteplase Before Interhospital Transfer for Thrombectomy in Acute Basilar Artery Occlusion
NCT07203625Phase 4Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenecteplase in ischemic stroke and basilar artery occlusion (BAO) (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Dichotomized modified Rankin Scale of 0-2 vs. 3-6 at 90 days. Started Jan 2026; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic strokebasilar artery occlusion (BAO)
Beyond the preview
Go deeper on NCT07203625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07203625.